Cardiological Findings in Children and Adolescents Before and After Guanfacine Treatment for Attention Deficit and Hyperactivity Disorder

被引:0
作者
Yukcu, Bekir [1 ]
Onal, Bedia Sultan [2 ]
Osmanli, Cansu Cobanoglu [2 ]
Tonkaz, Gulsum Yitik [2 ]
Sahin, Berkan [2 ]
机构
[1] Giresun Matern & Children Training & Res Hosp, Dept Pediat Cardiol, TR-28200 Giresun, Turkiye
[2] Giresun Univ, Dept Child & Adolescent Psychiat, Fac Med, TR-28200 Giresun, Turkiye
来源
CHILDREN-BASEL | 2025年 / 12卷 / 03期
关键词
ADHD; guanfacine; cardiovascular safety; electrocardiography; EXTENDED-RELEASE GUANFACINE; DEFICIT/HYPERACTIVITY DISORDER; DOUBLE-BLIND; ALPHA-2; AGONISTS; LONG-TERM; TP-E/QT; ADHD; STIMULANT; PSYCHOSTIMULANTS; METAANALYSIS;
D O I
10.3390/children12030302
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective: This study evaluates the short-term cardiovascular effects of guanfacine treatment in children and adolescents with attention deficit/hyperactivity disorder (ADHD). The treatment's impact on novel electrocardiographic parameters was also investigated. Methods: In a retrospective study conducted between January 2023 and June 2024, 37 patients aged 6-18 years with ADHD underwent baseline and follow-up cardiac evaluations including electrocardiography (ECG) and blood pressure measurements. Novel ECG markers (QRS-T angle, QT dispersion, QTc dispersion, Tp-e interval, Tp-e dispersion, Tp-e/QT ratio, and Tp-e/QTc ratio) were analyzed alongside standard parameters such as heart rate, QT, and corrected QT (QTc) intervals. Guanfacine was initiated at 1 mg and titrated weekly until an optimal clinical response was achieved. Results: Guanfacine treatment led to a significant reduction in heart rate (-12.3 bpm; p < 0.001) and P wave axis (-12.3 degrees; p = 0.038) and an increase in QT interval (+16.8 ms; p = 0.014). However, no significant changes were observed in blood pressure, QTc duration, or the novel ECG parameters. Importantly, the absence of any changes in these advanced markers supports the cardiovascular safety of guanfacine. Two patients experienced side effects (bradycardia and hypotension), leading to treatment discontinuation. ANCOVA analysis indicated that the duration between ECG evaluations significantly influenced the QT interval changes, emphasizing the importance of timing when monitoring cardiovascular effects. Conclusions: Guanfacine demonstrated minor, statistically significant effects on the selected cardiac parameters without clinically meaningful changes to or adverse impacts on the novel ECG markers investigated. As extended-release guanfacine has only been available in T & uuml;rkiye for the management of ADHD for approximately two years, studies evaluating its clinical efficacy and side effects are critical for clinicians working in this field.
引用
收藏
页数:14
相关论文
共 48 条
  • [41] Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children
    Silver, LB
    [J]. PEDIATRIC CLINICS OF NORTH AMERICA, 1999, 46 (05) : 965 - +
  • [42] Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
    Spencer, Thomas J.
    Greenbaum, Michael
    Ginsberg, Lawrence D.
    Murphy, William Rory
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (05) : 501 - 510
  • [43] Remission versus response as the goal of therapy in ADHD: A new standard for the field?
    Steele, Margaret
    Jensen, Peter S.
    Quinn, Declan M. P.
    [J]. CLINICAL THERAPEUTICS, 2006, 28 (11) : 1892 - 1908
  • [44] Cardiovascular Effects of Methylphenidate, Amphetamines and Atomoxetine in the Treatment of Attention-Deficit Hyperactivity Disorder
    Stiefel, Gary
    Besag, Frank M. C.
    [J]. DRUG SAFETY, 2010, 33 (10) : 821 - 842
  • [45] Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis
    Thomas, Rae
    Sanders, Sharon
    Doust, Jenny
    Beller, Elaine
    Glasziou, Paul
    [J]. PEDIATRICS, 2015, 135 (04) : E994 - E1001
  • [46] A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder
    Wilens, Timothy E.
    Bukstein, Oscar
    Brams, Matthew
    Cutler, Andrew J.
    Childress, Ann
    Rugino, Thomas
    Lyne, Andrew
    Grannis, Kara
    Youcha, Sharon
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2012, 51 (01) : 74 - 85
  • [47] Pediatric guanfacine exposures reported to the National Poison Data System, 2000-2016
    Winograd, Emily Jaynes
    Sollee, Dawn
    Schauben, Jay L.
    Kunisaki, Thomas
    Smotherman, Carmen
    Gautam, Shiva
    [J]. CLINICAL TOXICOLOGY, 2020, 58 (01) : 49 - 55
  • [48] ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
    Wolraich, Mark
    Brown, Lawrence
    Brown, Ronald T.
    DuPaul, George
    Earls, Marian
    Feldman, Heidi M.
    Ganiats, Theodore G.
    Kaplanek, Beth
    Meyer, Bruce
    Perrin, James
    Pierce, Karen
    Reiff, Michael
    Stein, Martin T.
    Visser, Susanna
    [J]. PEDIATRICS, 2011, 128 (05) : 1007 - 1022